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years following that event. RESULTS: A total of 10,335 patients
were identiﬁed; 8444 with IS and 1891 with HS. Increases in
medical costs during the four year post index period were as
follows for HS patients: without co-morbidities, $14,745; with
hypertension, $22,667; with hypertension plus type 2 diabetes
(T2D), $29,662; with hypertension plus congestive heart failure
(CHF), $26,768; with hypertension plus T2D plus CHF,
$34,302. For IS patients, these costs were $17,000 for IS-only
patients, but ranged from $21,344–$30,987 for IS patients with
other comorbidities. Results from multivariate analyses sup-
ported the validity of the descriptive statistics. CONCLUSION:
Comorbidities/risk factors contribute substantial incremental
costs to the already high economic burden of both HS and IS
stroke.
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OBJECTIVE: The morbidity of acute myocardial infarction
(AMI) is remarkable in Hungary, therefore it is inevitable to
understand the disease burden more accurately. Our aim was to
assess the burden of AMI in Hungary between 2003 and 2005.
We studied how much burden AMI patients impose on the
ﬁnancer (National Health Insurer Fund Administration—
NHIFA) in the inpatient and outpatient care and we estimated
the size of indirect social costs, too. METHODS: We extracted
the data of ‘new’ AMI patients (ICD-10: I21 main diagnosis but
not treated with the same diagnosis in the previous 24 months)
hospitalized in May 2003 from the database of the ﬁnancer. We
analyzed inpatient treatment costs of these patients in the period
of 12 months before the AMI and in the following ﬁrst and
second 12 months. Data were distributed by sex and age (age
groups: 25–44, 45–64, over 65). Other costs were estimated
after expert consultations. RESULTS: Average health insurance
costs of AMI’s active hospital care in the ﬁrst 12 months are
generally higher in females as in males; €1905.2 vs. €1564.4 (65
and over), €1716.4 vs. €1557.6 (45–64) and €918.0 vs. €962.4
(25–44). The burden in the chronic care is €60–160 per patient
in the ﬁrst year, which is similar to the active care costs in the
23rd to 24th months after the AMI (€88–216). CONCLUSION:
NHIFA was estimated to spend 17.6 million Euros on direct
health care on behalf of the nearly 12,000 annual AMI patients
in the ﬁrst 12 months. Avoiding one AMI could save €1380–
2260 (depending on gender and age) direct health care cost in
the ﬁrst 12 months. According to our estimate, the annual indi-
rect costs of AMI exceed €3.36 million (€711.3/patient) in the
working age group.
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OBJECTIVE: To examine variation in outlier payments across
U.S. hospitals and the extent which variation is explained by
patient and hospital factors, including quality of care.
METHODS: Using the national Medicare claims database for
2002, we examined outlier payments in patients undergoing
coronary artery bypass grafting (CABG) (n = 165,226). We
then categorized hospitals performing these procedures accord-
ing to their outlier payment rates. Using multiple logistic regres-
sion, we explored the relationships between hospital outlier
payment rates, patient case mix and hospital quality, as
reﬂected by risk-adjusted mortality rates. RESULTS: The pro-
portion of patients associated with outlier payments was 14%
(CABG). Average outlier payments were considerable: $24,000
per patient, costing Medicare more than half a billion dollars.
Risk factors for outlier payments were race and admission
acuity. Higher hospital and surgeon volumes and teaching
status were associated with lower rates of outlier payments.
There was a negative correlation between risk-adjusted mortal-
ity rates and outlier payments. The proportion of outlier pay-
ments was greater than 20 percent. Measurable patient and
hospital factors explained a small proportion of variation
across hospitals. CONCLUSION: Outlier payments in CABG
are an important component of medical costs with inpatient
surgery. Although explained in part by quality, reasons for wide
variation in outlier payments across hospitals remain to be
clariﬁed.
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OBJECTIVE: We evaluated the likelihood and cost of adverse
events (AE) by choice of acute conversion therapy for atrial
ﬁbrillation (AF) in hospitalized patients. METHODS: We
extracted Premier Perspective(tm) 2004–2005 discharges with
primary AF diagnosis and treatment with electric conversion
(EC) or IV anti-arrhythmic agent (AA; either amiodarone, ibutil-
ide or procainamide). We estimated odds ratios and inpatient
costs attributable to any AE, hypotension AE, or dysrhythmia AE
based on treatment, adjusting for comorbid, demographic and
hospital-speciﬁc factors. RESULTS: Out of 74,072 discharges
initially treated with EC (32%), amiodarone (49%), ibutilide
(11%) or procainamide (8%), approximately 28% (20,808) had
a treatment-related AE. Of these, 24% had hypotension and
37% experienced dysrhythmia. Odds ratios for any AE were
signiﬁcantly higher when initial treatment was amiodarone vs.
EC (OR; 95% CI) (1.24; 1.20–1.29), amiodarone vs. procaina-
mide (1.36; 1.27–1.46) and amiodarone vs. ibutilide (1.58; 1.48–
1.68). A similar pattern was observed for hypotension AE. Initial
treatment with EC increased the likelihood of dysrhythmia AE
vs. amiodarone (1.23; 1.16–1.30), ibutilide (1.21; 1.11–1.33)
and procainamide (1.29; 1.16–1.44). Adjusted costs for dis-
charges with any AE were signiﬁcantly higher vs. discharges
without AE (P < 0.0001). AE among patients receiving an AA
had the highest cost impact, contributing an average of $2702
in additional adjusted costs. Hypotension and dysrhythmia AE
among patients receiving AA were associated with $1232 and
$1054 in additional adjusted costs, respectively (P < 0.0001).
Among patients receiving EC, any AE, dysrhythmia and hypoten-
sion AE were associated with $2128 (P < 0.0001), $1655
(P < 0.0001) and no signiﬁcant (P = 0.21) increase in costs,
respectively. CONCLUSION: The likelihood of AE is associated
with choice of initial AF therapy. Patients initially treated with
amiodarone have the highest likelihood of AE, particularly
hypotension AE; those treated initially with EC have a higher
likelihood of dysrhythmia AE. Incremental costs attributable to
AE are substantial in this population.
A200 Abstracts
